Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

CYC 202

Known as: CYC-202, CYC202 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
Seliciclib (CYC202; R-roscovitine) is the first selective, orally bioavailable inhibitor of cyclin-dependent kinases 1, 2, 7 and… Expand
  • table 1
  • table 2
  • table 3
  • figure 2
  • figure 1
Highly Cited
2006
Highly Cited
2006
Apoptosis is essential for clearance of potentially injurious inflammatory cells and subsequent efficient resolution of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2005
Highly Cited
2005
(R)-Roscovitine (CYC202) is often referred to as a “selective inhibitor of cyclin-dependent kinases.” Besides its use as a… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2005
Highly Cited
2005
Seliciclib (CYC202, R-roscovitine) is a cyclin-dependent kinase (CDK) inhibitor that competes for the ATP binding site on the… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Review
2005
Review
2005
Cyclin-dependent kinases (CDKs) have long been known to be the main facilitators of the cell proliferation cycle. However, they… Expand
Highly Cited
2005
Highly Cited
2005
Cyclin-dependent kinase (CDK) inhibitors have the potential to induce cell-cycle arrest and apoptosis in cancer cells. Seliciclib… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Highly Cited
2004
Highly Cited
2004
Deregulation of the cell cycle commonly occurs during tumorigenesis, resulting in unrestricted cell proliferation and… Expand
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • figure 5
Review
2003
Review
2003
This article reviews the steps that have led us from very fundamental research on the cell division cycle, investigated with the… Expand
Review
2003
Review
2003
Aberrations in cell cycle progression occur in the majority of human malignancies. The main pathway affected is the… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
Highly Cited
2002
Highly Cited
2002
CDK2 inhibitors have been proposed as effective anti‐cancer therapeutics. We show here that CYC202 (R‐roscovitine) is a potent… Expand